Ayisha Sharma is a Biopharma Breaking News Reporter for Endpoints News. With a focus on the biopharmaceutical industry, Ayisha covers breaking news, clinical trial results, regulatory updates, and business developments within the sector. Her reporting provides valuable insights into the latest advancements and trends in the biopharma field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ayisha Sharma's coverage is primarily focused on the healthcare and pharmaceutical industry, with a strong emphasis on corporate developments, clinical trials, and regulatory actions. Her articles largely feature press releases and cite data from private sector announcements. Therefore, she may be particularly interested in pitches that provide exclusive access to breaking news within the pharmaceutical or biotech industries.
Given her focus on specific companies' activities such as licensing deals, FDA warnings, bankruptcies, and legal disputes within the healthcare sector; experts who have insights into these areas would likely capture her attention.
Ayisha's reporting does not seem to have a geographic focus but rather covers global developments in the pharmaceutical and biotech sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
It's been a tough few months for Corcept Therapeutics. In October, the company's lead pipeline candidate missed the primary endpoint in a …
Gilead Sciences has tapped Sanofi's Dietmar Berger as its next chief medical officer in a bid to shake up its strategy at the tail end …
By: Ayisha Sharma
This year's San Antonio Breast Cancer Conference yielded major clinical updates on some of the hottest areas of oncology, from VEGF bispecifics …
By: Ayisha Sharma
Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just eight months after debuting on …
By: Gene Tx
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell …
By: Ayisha Sharma
Edgewise Therapeutics' treatment candidate for several forms of muscular dystrophy has hit the primary endpoint in a mid-stage study, setting in motion plans for regulatory …
By: Ayisha Sharma
After multiple clinical failures, it's finally the end of the road for Merck's TIGIT program. The company is dropping development of its anti-TIGIT candidate vibostolimab …
Roche's alpha-synuclein-targeting antibody has failed to slow the progression of motor symptoms in a mid-stage Parkinson's disease test, marking the latest setback in a largely …
By: Ayisha Sharma
In a major reset to round off the year, Aadi Bioscience is divesting its only marketed product and in-licensing a trio of ADCs developed by …
By: Ayisha Sharma
Plus, news about Pyxis, Epitopea and Genevant: Idorsia's deal for blood pressure drug hits snag: The Swiss company
(833) 317-6278 
